5/21/2014 9:32:31 AM
ROCKVILLE, Md., May 20, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that United Therapeutics Corporation (Nasdaq:UTHR) has paid Supernus a $2 million milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram™ (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram™ utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram™, and may become entitled to additional milestone payments.
Help employers find you! Check out all the jobs and post your resume.
comments powered by